ATLANTA, Feb. 13 CryoLife, Inc. (NYSE: CRY), abiomaterials, medical device and tissue processing company, announced todaythat it is scheduled to participate in the Roth Capital Partners 20th AnnualOC Growth Stock Conference, February 19, 2008 at the Ritz Carlton LagunaNiguel in Dana Point, Calif.
D. Ashley Lee, executive vice president, chief operating officer and chieffinancial officer of CryoLife, Inc., will present Tuesday, February 19 at 8:30a.m., Pacific Time.
CryoLife's live presentation may be accessed through its Web site,www.cryolife.com, on the Investor Relations page. An archived copy of thepresentation will be available for 90 days on the same Web site.
Founded in 1984, CryoLife, Inc. is a leader in the processing anddistribution of implantable living human tissues for use in cardiac andvascular surgeries throughout the United States and Canada. The Companyrecently received FDA clearance for its CryoValve(R) SG pulmonary human heartvalves, processed using CryoLife's proprietary SynerGraft(R) Technology. TheCompany's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct tosutures and staples for use in adult patients in open surgical repair of largevessels. BioGlue is also CE marked in the European Community and approved inCanada and Australia for use in soft tissue repair. The Company alsodistributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CEmarked for distribution within the European Community.
For additional information about the Company, visit CryoLife's Web Site:http://www.cryolife.com.Media Contacts: D. Ashley Lee Katie Brazel Executive Vice President, Chief Financial Officer Fleishman Hillard and Chief Operating Officer Phone: 770-419-3355 Phone: 404-739-0150
SOURCE CryoLife, Inc.